- Home
- SMWB vs TRVI Comparison
SMWB vs TRVI Comparison
Compare SMWB & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMWB
- TRVI
- Stock Information
- Founded
- SMWB 2007
- TRVI 2011
- Country
- SMWB Israel
- TRVI United States
- Employees
- SMWB N/A
- TRVI N/A
- Industry
- SMWB Computer Software: Programming Data Processing
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- SMWB Technology
- TRVI Health Care
- Exchange
- SMWB Nasdaq
- TRVI Nasdaq
- Market Cap
- SMWB 686.7M
- TRVI 725.7M
- IPO Year
- SMWB 2021
- TRVI 2019
- Fundamental
- Price
- SMWB $8.44
- TRVI $5.72
- Analyst Decision
- SMWB Strong Buy
- TRVI Strong Buy
- Analyst Count
- SMWB 8
- TRVI 8
- Target Price
- SMWB $15.75
- TRVI $19.31
- AVG Volume (30 Days)
- SMWB 463.5K
- TRVI 2.6M
- Earning Date
- SMWB 08-05-2025
- TRVI 08-07-2025
- Dividend Yield
- SMWB N/A
- TRVI N/A
- EPS Growth
- SMWB N/A
- TRVI N/A
- EPS
- SMWB N/A
- TRVI N/A
- Revenue
- SMWB $258,017,999.00
- TRVI N/A
- Revenue This Year
- SMWB $16.87
- TRVI N/A
- Revenue Next Year
- SMWB $14.96
- TRVI N/A
- P/E Ratio
- SMWB N/A
- TRVI N/A
- Revenue Growth
- SMWB 15.06
- TRVI N/A
- 52 Week Low
- SMWB $5.71
- TRVI $2.36
- 52 Week High
- SMWB $17.64
- TRVI $7.48
- Technical
- Relative Strength Index (RSI)
- SMWB 56.89
- TRVI 38.79
- Support Level
- SMWB $7.38
- TRVI $5.41
- Resistance Level
- SMWB $7.99
- TRVI $5.96
- Average True Range (ATR)
- SMWB 0.35
- TRVI 0.29
- MACD
- SMWB 0.02
- TRVI -0.07
- Stochastic Oscillator
- SMWB 61.59
- TRVI 14.87
About SMWB Similarweb Ltd.
Similarweb Ltd provides digital data and analytics that power critical business decisions. The group recognizes revenue from subscriptions to the platform and other subscription products on a straight-line basis over the term of the contract subscription period beginning on the date access to the platform is granted, provided all other revenue recognition criteria have been met. It has geographic presence in Israel, the United States, the United Kingdom, Asia Pacific, Europe, and Other. The group generates the majority of its revenue from the United States.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.